Parkinson’s disease is one of the fastest-growing neurological disorders worldwide, supported by a robust and diverse clinical research pipeline. As understanding of disease biology continues to advance, there is growing recognition that traditional trial designs and endpoints may not fully reflect the complexity and variability of Parkinson’s disease progression.
This white paper explores how advances in endpoint science, digital health technology, and artificial intelligence are shaping a new generation of Parkinson’s disease trials. By integrating multimodal data, adaptive designs, and validated digital biomarkers, sponsors can enhance sensitivity to treatment effects, reduce operational burden, and support regulatory confidence—helping translate scientific progress into meaningful clinical outcomes.
What’s Inside
- The current Parkinson’s disease landscape and implications for clinical development
- How established endpoints can be complemented by multimodal and digital measures
- The role of wearable technologies and remote data capture in trial efficiency and patient experience
- Applications of artificial intelligence to support patient stratification, endpoint interpretation, and adaptive trial designs
- Regulatory and operational considerations for integrating novel endpoints and data strategies
Download the White Paper
